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Neuromyelitis optica spectrum disorders 
Portugal 
A B S T R A C T   
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare disorder in which astrocyte damage and/ 
or demyelination often cause severe neurological deficits. 
Objective: To identify Portuguese patients with NMOSD and assess their epidemiological/clinical characteristics. 
Methods: This was a nationwide multicenter study. Twenty-four Portuguese adult and 3 neuropediatric centers 
following NMOSD patients were included. 
Results: A total of 180 patients met the 2015 Wingerchuk NMOSD criteria, 77 were AQP4-antibody positive 
(Abs+), 67 MOG-Abs+, and 36 seronegative. Point prevalence on December 31, 2018 was 1.71/100,000 for 
NMOSD, 0.71/100,000 for AQP4-Abs+, 0.65/100,000 for MOG-Abs+, and 0.35/100,000 for seronegative 
NMOSD. A total of 44 new NMOSD cases were identified during the two-year study period (11 AQP4-Abs+, 27 
MOG-Abs+, and 6 seronegative). The annual incidence rate in that period was 0.21/100,000 person-years for 
NMOSD, 0.05/100,000 for AQP4-Abs+, 0.13/100,000 for MOG-Abs+, and 0.03/100,000 for seronegative 
NMOSD. 
AQP4-Abs+ predominated in females and was associated with autoimmune disorders. Frequently presented with 
myelitis. Area postrema syndrome was exclusive of this subtype, and associated with higher morbidity/mortality 
than other forms of NMOSD. MOG-Ab+ more often presented with optic neuritis, required less immunosup-
pression, and had better outcome. 
Conclusion: Epidemiological/clinical NMOSD profiles in the Portuguese population are similar to other European 
countries   
1. Introduction 
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing 
inflammatory disease of the central nervous system (CNS), (Wein-
shenker and Wingerchuk, 2017; Flanagan and Weinshenker, 2014) but 
probably the most common of non-multiple sclerosis (MS) inflammatory 
demyelinating diseases (IDDs) of the CNS (Flanagan and Weinshenker, 
2014; Leite et al., 2012). 
The discovery in 2005 of circulating pathogenic immunoglobulin G1 
(IgG1) antibodies against the astrocyte water channel protein aquaporin 
4 (AQP4) associated with neuromyelitis optica revolutionized the un-
derstanding of the disease (Papadopoulos, 2009). 
The diagnostic criteria developed by the International Panel for 
NMOSD Diagnosis in 2015 (Wingerchuk et al., 2015) enabled to di-
agnose (i) NMOSD with AQP4 antibodies (AQP4-Abs+) with at least one 
of six core clinical symptoms and (ii) NMOSD seronegative for AQP4 
antibodies with at least two of six core clinical features (one of which 
being one of the three most common: optic neuritis, transverse myelitis, 
or area postrema syndrome) and evidence from magnetic resonance 
imaging (MRI). (Wingerchuk et al., 2015; Papp et al., 2018) Anti-myelin 
oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs+) are 
detected in a proportion of NMOSD patients who are seronegative for 
AQP4 antibodies (Jarius et al., 2016; Sato et al., 2014). 
NMOSD is now a well-established heterogeneous CNS IDD, distinct 
and with a different treatment approach from MS (Trebst et al., 2014). 
Early diagnosis with prompt acute treatment and adequate prophylactic 
chronic immunotherapy are crucial to prevent disability. Data about 
NMOSD epidemiology and disease characteristics are crucial for 
adequate healthcare resource allocation, namely related to the use of 
specific therapies, and have been missing in Portugal until now (Wein-
shenker and Wingerchuk, 2017). This led us to conduct a national study 
on these patients, although according to the Portuguese population 
characteristics and healthcare services we could suspect to find analo-
gous results to other European countries, especially those with similar 
latitude. 
2. Objective 
A clinical-based NMOSD survey was undertaken in the Portuguese 
population using the revised diagnostic criteria (2015 IPND criteria) 
(Wingerchuk et al., 2015), with the main objective of characterizing its 
epidemiology (point prevalence and incidence). The analysis of de-
mographics and clinical features was the secondary aim. 
3. Materials and methods 
3.1. Study setting 
According to the 2018 National Statistics Institute (INE) report, the 
resident Portuguese population on December 31, 2018 was 10,276,617 
persons (INE and de Portugal, 2020). 
In Portugal, NMOSD patients are mostly treated in public hospitals 
(part of the National Health Service). Even when diagnosis is suspected 
in private institutions, patients are referred to public hospitals for 
further workup and management. They are usually followed and treated 
by neurologists who also manage MS patients. This study was planned 
and discussed during meetings of the Portuguese Multiple Sclerosis 
Study Group (Grupo de Estudos de Esclerose Múltipla) and Portuguese 
Society of Neurology, to ensure that all neurologists treating NMOSD 
patients would be included, from patient identification to respective 
data collection. 
This was a nationwide multicenter study. Public hospitals with at 
least one neurologist or Neuropediatrics Unit treating MS patients were 
invited to attend meetings and participate in the study. 
Data was collected between January 1, 2018 and December 31, 
2019. Both public and private hospitals managing NMOSD patients were 
invited to participate. Their names are listed in the author affiliations’ 
section. All patients with NMOSD identified during that time period 
were included, namely those with disease onset before January 1, 2018 – 
prevalent population − and those with disease onset and NMOSD 
diagnosis during the study period − incident population. 
A total of 43 Portuguese public hospitals and one private hospital 
were invited to participate. Seventeen did not treat NMOSD patients, 
only referring them to larger institutions. The remaining 24 adult cen-
ters and three Neuropediatric Units were included in the study. 
All patients signed informed consent to participate, and anonymized 
data was inserted in an electronic database. 
3.2. Identification of NMOSD patients 
Patient information was retrieved from hospital clinical databases 
and/or Neurology clinical records. NMOSD diagnosis was confirmed by 
reviewing patients’ medical records. Retrieved information included 
sociodemographic and clinical data. Patients who had not been tested 
for anti-AQP4 and/or anti-MOG antibodies or who were antibody- 
negative by local standard assays were asked to provide a blood sam-
ple for antibody testing. 
During the study period, all neurologists from participating centers 
E. Santos et al.                                                                                                                                                                                                                                  
Multiple Sclerosis and Related Disorders 56 (2021) 103258
3
were regularly contacted to register new patients, complete missing 
clinical data, and collect patients’ blood samples as appropriate. 
3.3. NMOSD subgroup classification 
Patients with NMOSD diagnosis were identified based on the 2015 
IPND criteria (Wingerchuk et al., 2015) and divided in three groups: 
AQP4-Abs+ subgroup, MOG-Abs+ subgroup, and seronegative sub-
group. All cases were validated by the two neurologists who were 
principal investigators in this study (ES, MJS). 
3.4. Clinical data collection 
Clinical and demographic data were collected from patients’ medical 
records and included date of birth, current age, gender, ethnicity, age at 
NMOSD onset, age at NMOSD diagnosis, presence of other autoimmune 
disorders, clinical presentation, number of relapses, MRI results, cere-
brospinal fluid (CSF) results, AQP4-Abs, MOG-Abs, and other auto- 
antibodies study, Expanded Disability Status Scale (EDSS) score, and 
treatments used during the course of disease. Brain and spinal cord MRI 
imaging was performed in all patients and data was collected based on 
the reports, and not on protocoled analysis of the images. 
All data was recorded in a single anonymous database specifically 
designed for this study. 
3.5. AQP4 and MOG antibody assays 
All patients positive for anti-AQP4 or anti-MOG antibodies according 
to local tests were not tested again. Those tests included three different 
assays: a commercial fixed cell-based assay (Euroimmun®, Germany), a 
live, in house, cell-based assay (Oxford, UK), and a live cell Fluorescence- 
Activated Cell Sorting (FACS) assay (Mayo Clinic, EUA). 
Negative results for anti-AQP4 were reanalysed and if again negative 
the sample was tested for anti-MOG antibodies. These tests were con-
ducted in Centro Hospitalar Universitario do Porto (CHUP) using a fixed 
cell-based assay (Euroimmun®, Germany) according to the manufac-
turer’s instructions. Results were considered positive if a typical fluo-
rescence pattern was observed on transfected cells. 
3.6. Statistical analysis 
Point prevalence date was set on December 31, 2018 for all patients 
alive and resident in the study area. The 10,276,671 residents in 
Portugal on December 31, 2018 comprised prevalence denominator. 
Annual incidence rate refers to all incident cases in the country 
throughout the 2018-2019 study period. To estimate the number of 
person-years for the incidence denominator, the mid period number of 
10,276,671 estimated residents was multiplied by two. Prevalence and 
annual incidence rate were calculated per 100,000 inhabitants for all 
NMOSD patients and respective subgroups. 
Poisson distribution was used to calculate confidence intervals for 
incidence and prevalence (Papp et al., 2018). Pearson’s chi-squared test 
(χ2) was used to assess the association between some categorical vari-
ables and the NMOSD serological type. In one case, the independent 
variable (age) was continuous and comparison of means was performed. 
For these analyses, SPSS statistics, version 25 was used. 
3.7. Ethical approval 
Ethical approval for patient data collection and blood collection 
when necessary was obtained from the Ethics Committees of partici-
pating hospitals and from the Portuguese Data Protection Authority 
(Comissão Nacional de Proteção de Dados). Informed consent was addi-
tionally retrieved from participating patients. 
4. Results 
4.1. Epidemiological characteristics 
A total of 191 patients with NMOSD diagnosis according to Wing-
erchuk 2015 criteria were identified. Of these, 180 had known sero-
logical information for AQP4 and MOG antibodies and were included 
and eleven patients who only had information on AQP4 antibodies were 
excluded. 
Of the 180 patients included, 144 were seropositive (77 had AQP4 
and 67 MOG antibodies) and 36 seronegative. Four patients with anti- 
AQP4 antibodies died during the study period, three due to the dis-
ease and one from a respiratory infection. 
The point prevalence on December 31, 2018 was 1.71/100,000 for 
NMOSD (95% confidence interval [CI] 1.47-1.98), 0.71/100,000 for 
AQP4-Abs+ subgroup (95% CI 0.56-0.90), 0.65/100,000 for MOG-Abs+
subgroup (95% CI 0.50-0.83), and 0.35/100,000 for seronegative sub-
group (95% CI 0.24-0.48). 
Forty-four new NMOSD cases were identified during the study period 
(27 in 2018 and 17 in 2019), 38 of which seropositive (11 AQP4-Abs+, 
27 MOG-Abs+) and six seronegative. 
The annual incidence rate between 2018-2019 was 0.21 per 100,000 
person-years for NMOSD (44/[10276617 × 2]; 95% CI 0.16-0.29), 0.05 
per 100,000 person-years for AQP4-Abs+ subgroup (95% CI 0.03-0.10), 
0.13 per 100,000 for MOG-Abs+ subgroup (95% CI 0.09-0.20), and 0.03 
per 100,000 person-years for seronegative subgroup (95% CI 0.01-0.06). 
4.2. Demographic and clinical features 
Tables 1 and 2 show the main demographic and clinical features of 
the three patient subgroups and Fig. 1 depicts the number of NMOSD 
cases by serological type, age at first symptoms, and sex. 
The female:male ratio was significantly higher in the AQP4-Abs+
subgroup compared with the other two patient subgroups (7.5:1 vs 1.8:1 
in MOG-Abs+ subgroup vs 1.7:1 in seronegative subgroup, p=0.001) 
(Fig. 1). Non-Caucasians accounted for 10.4% of patients in AQP4-Abs+
subgroup, 3.0% in MOG-Abs+ subgroup, and 2.8% in seronegative 
subgroup (p=0.327). 
Table 1 
Demographic characteristics of NMOSD patients with AQP4 antibodies, MOG 
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AQP4 Abs+, anti-astrocyte water channel protein aquaporin 4 antibodies- 
positive; MOG Abs+, anti-myelin oligodendrocyte glycoprotein antibodies- 
positive. 
Bold entries indicate statistical significance (p<0.05). 
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Age at disease onset was variable in all three subgroups, ranging 
from childhood to elderly, although AQP4-Abs+ disease seemed to 
affect, on average, older people compared to the other subgroups. 
The first disease clinical manifestation was myelitis in 45.4% and 
optic neuritis in 32.5% of patients in the AQP4-Abs+ subgroup, whereas 
in MOG-Abs+ subgroup optic neuritis was the most common clinical 
presentation (44.8%), followed by myelitis (32.8%). In the seronegative 
subgroup, 58.3% of patients presented with myelitis and 25.0% with 
optic neuritis (p=0.016). Clinical area postrema syndrome was only 
identified in seven patients in the AQP4-Abs+ subgroup, being an iso-
lated presentation in five. 
Simultaneous optic neuritis and myelitis at presentation was more 
common in the MOG-Abs+ subgroup (10.4% vs 5.2% in AQP4-Abs+
subgroup vs 2.8 in seronegative subgroup; p=0.016). Nine percent (6/ 
67) of MOG-Abs+ patients had bilateral and simultaneous optic neuritis 
(Table 2). 
Most patients reported one or two relapses in the first two years of 
disease (Table 2). Differences in relapse number between the three 
subgroups were not statistically significant. 
Although no significant differences were observed in disease severity 
as measured by EDSS at nadir between the three subgroups, most severe 
EDSS cases (7− 10 score) belonged to the AQP4-Abs+ subgroup 
(Table 2). 
Association with other autoimmune diseases was more common in 
AQP4-Abs+ subgroup (26.7% vs 4.5% in anti-MOG Abs+ subgroup vs 
12.9% in seronegative subgroup; p<0.0001). 
4.3. MRI findings 
MRI findings in the study cohort are depicted in Table 3. We got MRI 
data from 139 patients of the 180 NMOSD patients identified. 
Brainstem involvement was significantly higher in MOG-Abs+ pa-
tients. Lesions in the area postrema, which contrast with the clinical 
syndrome, were identified in all patient subgroups (Table 3). 
Involvement of both optic nerves extending to the chiasma was 
recorded in 20% of all NMOSD patients. Isolated chiasma involvement 
was not found in the seronegative subgroup. 
Supratentorial lesions were more frequent in the MOG-Abs+ sub-
group, although the difference was not statistically significant. MRI with 
typical acute demyelinating encephalomyelitis features was not identi-
fied in this cohort. 
Conus medullaris lesions were more frequently found in MOG-Abs+
patients, whereas lesions in other spinal cord segments were equally 
reported in the three NMOSD subgroups. 
4.4. Laboratory findings 
Table 4 depicts laboratory findings in the three considered patient 
subgroups. Other autoantibodies (ANA, anti-SSA, anti-SSB, or anti- 
thyroid) were more common in the AQP4-Abs+ subgroup (39.4% vs 
3.3% in anti-MOG Abs+ subgroup vs 6.4% in seronegative subgroup, 
p<0.0001). 
CSF data was available in 80.6% of patients (145/180). Pleocytosis 
was present in 44.6% of the AQP4-Abs+ subgroup, 50.8% of the MOG- 
Abs+ subgroup, and 56.6% of the seronegative subgroup, which rep-
resented non-statistically significant differences (p=0.553). Average cell 
number was 34.1 cells/uL in AQP4-Abs+ subgroup, 45.8 cells/uL in 
MOG-Abs+ subgroup, and 90.4 cells/uL in seronegative subgroup 
(p=0.349). Oligoclonal bands were present in 25% of the AQP4-Abs+
subgroup, 18% of the MOG-Abs+ subgroup, and 16.7% of the sero-
negative group (p=0.563; Table 4). 
4.5. Treatment according to NMOSD subgroup 
Treatment received according to NMOSD patient subgroup are 
shown in Table 5. All patients with AQP4-Abs+ and seronegative disease 
and 92.5% of patients with MOG-Abs+ disease were treated with ste-
roids in relapse. Plasma exchange was used in 46.7% (28/60) of AQP4- 
Abs+, 11.3% (7/62) of MOG-Abs+, and 30.6% (11/36) of seronegative 
subgroup (p=0.001). 
Regarding chronic immunosuppressant treatment, rituximab was 
preferentially used in the AQP4-Abs+ subgroup (p=0.002). The number 
of immunosuppressants used was higher in the AQP4-Abs+ subgroup 
(p<0.0001). 
5. Discussion 
The reported prevalence of NMOSD is approximately 1/100,000 
among Caucasians, with an annual incidence of <1/million population 
(Hor et al., 2020; Dale et al., 2018 Jun). However, prevalence may be up 
to 10/100,000 in certain racial groups. Still, this is a low prevalence 
compared with MS, which ranges from 1–2/100,000 in the equatorial 
region and 150– 200/100,000 in Canada and northern Europe (Hor 
et al., 2020). 
Few NMOSD epidemiological studies have used the 2015 IPND 
criteria (Wingerchuk et al., 2015) or included AQP4-Abs+, MOG-Abs+, 
and double seronegative subgroups (Papp et al., 2018; Papp et al., 2020; 
Houzen et al., 2017 Nov 7). 
Table 2 
Clinical features of NMOSD patients with AQP4 antibodies, MOG antibodies, 
and seronegativity.  
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AQP4 Abs+, anti-astrocyte water channel protein aquaporin 4 antibodies- 
positive; EDSS, Expanded Disability Status Scale; Max, maximum; Min, mini-
mum; MOG Abs+, anti-myelin oligodendrocyte glycoprotein antibodies- 
positive; Nr, number; SD, standard deviation; Ukn, unknown. 
Bold entries indicate statistical significance (p<0.05). 
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Prevalence values identified in this study are similar to those found 
in Caucasian populations in Europe (Jarius et al., 2016; Hor et al., 2020), 
Middle East (Eskandarieh et al., 2017 Nov), and Australia (Sepúlveda 
et al., 2018) and lower than those reported in non-Caucasian pop-
ulations using the same diagnostic criteria (Papp et al., 2020; Bukhari 
et al., 2017). 
NMOSD prevalence in Australia and New Zealand has been esti-
mated in 0.55/100,000 (Bukhari et al., 2017), in Catalonia in 0.89/100, 
000 (Sepúlveda et al., 2018), in Denmark in 1.09/100,000 (Papp et al., 
2018), and in Sweden in 1.04/100,000 inhabitants (Jonsson et al., 
2019). 
A study from South Denmark reported an AQP4-Abs+ disease 
prevalence of 1.68/100,000 and of MOG-Abs+ disease of 4.4/100,000 
(Asgari et al., 2019). In the present study, prevalence of AQP4-Abs+
disease was 0.71/100,000 (95% CI 0.56-0.90) and of MOG-Abs+ disease 
was 0.65/100,000 (95% CI 0.50-0.83). 
Incidence rates found in this study in the Portuguese population were 
also similar to those reported in Europe (Catalonia and Denmark) and 
Australia (Hor et al., 2020; Sepúlveda et al., 2018; Hor et al., 2018). 
Regarding the possible effect of latitude on prevalence, data from 
Catalonia is the one closest to Portugal (Sepúlveda et al., 2018). 
The present multicenter nationwide study is the first investigating 
epidemiological and clinical features of the Portuguese NMOSD popu-
lation, including adults and pediatric patients. In absence of a central-
ized national disease or laboratory results registry, the medical records 
of patients included in databases of the 27 Portuguese centers where 
NMOSD patients are followed was the only source of identification of 
patients for inclusion in this study. Using a laboratory source was not an 
option in this study, since patients from different hospitals are tested in 
different laboratories, including private ones. 
With these limitations in mind and considering that NMOSD patients 
are almost always diagnosed and treated by or referred to neurologists, 
Fig. 1. Number of NMOSD cases by serological type, age at first symptoms, and sex.  
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this study was publicized several times in MS Portuguese meetings. 
This was a prospective study conducted over a two-year period, 
during which centers were regularly contacted to identify patients and 
register data. Due to this, the authors believe that the number of NMOSD 
patients identified is likely to be close to the reality of NMOSD patients 
in Portugal. 
Clinical and demographic data retrieved from this study are similar 
to those previously reported in other studies (Wingerchuk et al., 2015; 
Trebst et al., 2014; Jonsson et al., 2019; Quek et al., 2012). In the 
AQP4-Abs+ subgroup, there is stronger female predominance, other 
autoimmune disorders are more common, and non-Caucasians are more 
frequent. Myelitis is more frequently the initial manifestation in 
AQP4-Abs+ patients, whereas optic neuritis is the more common onset 
symptom in MOG-Abs+ counterparts. In this study, area postrema syn-
drome was highly predictive of AQP4-Abs+ status. 
In MRI study, MOG-Abs+ patients more frequently presented lumbar 
and conus medullaris lesions. Optic neuritis with chiasm involvement, 
diencephalon, and brainstem were more frequent in AQP4-Abs+
patients. 
Prognosis seems better in MOG-Abs+ compared to both AQP4-Abs+
and seronegative disease. As described in other studies, compared with 
other patient subgroups AQP4-Abs+ patients are more likely to have 
more relapses and more severe disease, present higher EDSS, (Sato et al., 
2014; Wingerchuk et al., 1999) and require more aggressive treatment. 
6. Conclusions 
This was a nationwide study of AQP4-Abs+, MOG-Abs+, and double 
seronegative NMOSD classified according to the 2015 IPND criteria, 
which enabled to retrieve an epidemiological and clinical picture of the 
Portuguese NMOSD population. 
NMOSD associated with AQP4 or MOG antibodies is a very rare 
autoimmune condition of the CNS, with both disease subgroups pre-
senting distinguishing features. AQP4-Abs+ NMOSD is more often 
associated with female sex, non-Caucasian race, and other autoimmune 
diseases, has myelitis as main presenting syndrome, and is characterized 
by more severe attacks, with frequent use of plasma exchange or intra-
venous immunoglobulin and need for second-line immunosuppressants. 
MOG-Abs+ NMOSD is more often associated with (sometimes bilateral) 
optic neuritis as the commonest presenting feature, simultaneous optic 
neuritis and myelitis presentation, supratentorial disease, good intra-
venous methylprednisolone response, and lower requirement for 
chronic immunosuppression. 
NMOSD epidemiological, demographic, and clinical characteristics 
in Portugal are similar to those from other published series, including in 
Europe, suggesting an effective clinical and laboratory NMOSD diag-
nosis throughout the country. Although it is a rare disorder, the signif-
icant number of patients we found justifies the existence of reference 
centers, favouring clinical assessment and treatment by teams with 
growing and accumulated experience. 
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15 (10.8) 3 (5.0) 10 (20) 2 (6.9) 0.04 
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Cerebellum, n(%) 23 (16.6) 8 (13.3) 12 (24) 3 (10.3) 0.245 
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28 (20.1) 12 (20) 14 (28) 2 (6.9) 0.08 
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AQP4 Abs+, anti-astrocyte water channel protein aquaporin 4 antibodies- 
positive; AQP-4-/MOG-, anti-astrocyte water channel protein aquaporin 4 an-
tibodies and Anti-myelin oligodendrocyte glycoprotein antibodies negative; 
EDSS, Expanded Disability Status Scale; LETM, longitudinally extensive trans-
verse myelitis; Max, maximum; Min, minimum; MOG Abs+, anti-myelin oligo-
dendrocyte glycoprotein antibodies-positive; Nr, number; SD, standard 
deviation; Ukn, unknown; VLETM, very long longitudinally extensive transverse 
myelitis >12 segments. 
Bold entries indicate statistical significance (p<0.05). 
Table 4 
Laboratory findings of NMOSD patients with AQP4 antibodies, MOG antibodies, 












No   
25 (45%) 
31 (55%)  
(Not 
performed/ 
UKN =21)  
30 (51%) 
29 (49%)  
(Not 
performed/ 
UKN =8)  
17 (57%) 


























No   
11 (26%) 

















in the serum Yes 
No  
26 (39%) 





60 897%)  
(Not 
performed/ 
UKN =8)  
2 (6%) 





AQP4 Abs+, anti-astrocyte water channel protein aquaporin 4 antibodies- 
positive; CSF, cerebrospinal fluid; Max, maximum; Min, minimum; MOG 
Abs+, anti-myelin oligodendrocyte glycoprotein antibodies-positive; Nr, num-
ber; SD, standard deviation; Ukn, unknown. 
Pleocytosis was considered when >5 cells/ul. 
Bold entries indicate statistical significance (p<0.05). 
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Samões: Investigation, Resources. Ana Paula Sousa: Investigation, 
Resources. Sónia Figueiroa: Investigation, Resources. Teresa Men-
donça: Investigation, Resources. Pedro Abreu: Investigation, Re-
sources. Joana Guimarães: Investigation, Resources. Raquel Sousa: 
Investigation, Resources. Cláudia Melo: Investigation, Resources. Inês 
Correia: Investigation, Resources. Joao Durães: Investigation, Re-
sources. Lívia Sousa: Investigation, Resources, Writing – review & 
editing. João Ferreira: Investigation, Resources. João de Sá: Investi-
gation, Resources, Writing – review & editing. Filipa Sousa: Investi-
gation, Resources. Marta Sequeira: Investigation, Resources. Ana Sofia 
Correia: Investigation, Resources. Ana Luísa André: Investigation, 
Resources. Carlos Basílio: Investigation, Resources. Marta Arenga: 
Investigation, Resources. Irene Mendes: Investigation, Resources. Inês 
Brás Marques: Investigation, Resources. Sandra Perdigão: Investiga-
tion, Resources. Helena Felgueiras: Investigation, Resources. Ivânia 
Alves: Investigation, Resources. Filipe Correia: Investigation, 
Resources. Cândida Barroso: Investigation, Resources. Armando 
Morganho: Investigation, Resources. Cátia Carmona: Investigation, 
Resources. Filipe Palavra: Investigation, Resources, Writing – review & 
editing. Mariana Santos: Investigation, Resources. Vasco Salgado: 
Investigation, Resources. Adelaide Palos: Investigation, Resources. 
Hipólito Nzwalo: Investigation, Resources. Angela Timóteo: Investi-
gation, Resources. Rui Guerreiro: Investigation, Resources. Luís Isi-
doro: Investigation, Resources. Daniela Boleixa: Investigation, 
Resources. Paula Carneiro: Investigation, Resources. Esmeralda 
Neves: Investigation, Resources. Ana Martins Silva: Investigation, 
Resources, Conceptualization, Methodology, Writing – review & editing. 
Guilherme Gonçalves: Conceptualization, Methodology, Formal anal-
ysis, Writing – review & editing. Maria Isabel Leite: Conceptualization, 
Methodology, Visualization, Writing – review & editing. Maria José Sá: 
Investigation, Resources, Conceptualization, Methodology, Validation, 
Formal analysis, Data curation, Writing – review & editing, Funding 
acquisition. 
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